Results 181 to 190 of about 281,370 (287)

Unmasking intratumoral heterogeneity: Postoperative revelation of subclonal divergence in <i>de novo</i> metastatic HR-positive/HER2-negative breast cancer: A case report. [PDF]

Mol Clin Oncol
Birsin Z, Çerme E, Sönmez Wetherilt C, Turna ZH.   +3 more
europepmc   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer. [PDF]

Breast
Corti C, Li T, Martin AR, Hughes ME, Parker T, Duporte TS, Curigliano G, King TA, Mittendorf EA, Lin NU, Tayob N, Tolaney SM.   +11 more
europepmc   +1 more source

Association of recurrence patterns and outcome with HR and HER2 status in patients with resected brain metastases from breast cancer

International Journal of Cancer, EarlyView.
What's New? While treatment strategies for solid brain metastases have been relatively uniform across cancer subtypes, tailored approaches are warranted. In this observational study, intracranial recurrences after microsurgical resection occurred significantly earlier and more frequently at distant sites in patients with triple‐negative breast cancer ...
Jonathan Weller, Sophie Katzendobler, Frederic Thiele, Anna Riesberg, Patrick N. Harter, Frederick Klauschen, Rachel Wuerstlein, Stephan Schoenecker, Montserrat Pazos Escudero, Robert Forbrig, Niklas Thon, Florian Ringel, Michael Weller, Emilie Le Rhun, Veit M. Stoecklein   +14 more
wiley   +1 more source

HER2-specific synthetic antigen receptor T cell therapy synergizes with radiotherapy to provide improved antitumor efficacy in non-small cell lung cancer. [PDF]

J Leukoc Biol
Biziotis OD, Silvestri CM, Moore AE, Fayyazi R, Wang S, Ahmadi E, Del Rosso D, Ali A, Evelyn Tsakiridis E, Baker CL, Aarts CW, Bojovic B, Hammill JA, Steinberg GR, Bramson JL, Tsakiridis T.   +15 more
europepmc   +1 more source

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

International Journal of Cancer, EarlyView.
What's New? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld, Magdalena Ríos‐Romero, Huma Dar, Tommy Fornander, Gizeh Perez‐Tenorio, Helena Fohlin, Olle Stål, Julia Tutzauer, Linda S. Lindström   +8 more
wiley   +1 more source

From mechanism to phenotype: What fits in a basket trial

Epilepsia, EarlyView.
Kette D. Valente
wiley   +1 more source

Clinical implications of PD‐L1 expression in oncogene‐driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors

International Journal of Cancer, EarlyView.
What's New? PD‐L1 is a reliable biomarker for predicting immunotherapy efficacy in patients with non‐small‐cell lung cancer lacking oncogenic driver mutations. However, its significance in patients with driver mutations remains unclear. In this study of 273 patients with stage IV non–‐small‐cell lung cancer harboring diverse driver alterations and PD ...
Xiaoxiao Fan, Chenxi Wei, Minjun Rong, Shengnan Wang, Jiaying Wang, Xiaohan Wang, Xiao Han, Xue Meng   +7 more
wiley   +1 more source

Detection of actionable mutations in the cerebrospinal fluid and concordance/discordance with extracranial mutations in patients with metastatic breast cancer and leptomeningeal disease. [PDF]

Ther Adv Med Oncol
Huppert LA, Fisch S, Her L, Hodgdon C, Brain S, Simmons C, Lai AR, Malevanchik L, Balassanian R, Vasudevan HN, Morshed R, Braunstein S, Boreta L, Majure M, Chien AJ, Rugo HS, Magbanua MJM, Melisko ME.   +17 more
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, EarlyView.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source